NO962187D0 - Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav - Google Patents

Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav

Info

Publication number
NO962187D0
NO962187D0 NO962187A NO962187A NO962187D0 NO 962187 D0 NO962187 D0 NO 962187D0 NO 962187 A NO962187 A NO 962187A NO 962187 A NO962187 A NO 962187A NO 962187 D0 NO962187 D0 NO 962187D0
Authority
NO
Norway
Prior art keywords
compositions
methods
purifying
inhibit apoptosis
apoptosis
Prior art date
Application number
NO962187A
Other languages
English (en)
Other versions
NO962187L (no
Inventor
John D Bradley
L David Tomei
Philip J Barr
Original Assignee
Lxr Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lxr Biotechnology Inc filed Critical Lxr Biotechnology Inc
Publication of NO962187D0 publication Critical patent/NO962187D0/no
Publication of NO962187L publication Critical patent/NO962187L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
NO962187A 1993-11-30 1996-05-29 Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav NO962187L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15898093A 1993-11-30 1993-11-30
US08/320,155 US5759548A (en) 1993-11-30 1994-10-07 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
PCT/US1994/013649 WO1995015173A1 (en) 1993-11-30 1994-11-30 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Publications (2)

Publication Number Publication Date
NO962187D0 true NO962187D0 (no) 1996-05-29
NO962187L NO962187L (no) 1996-07-30

Family

ID=26855549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962187A NO962187L (no) 1993-11-30 1996-05-29 Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav

Country Status (14)

Country Link
US (8) US5759548A (no)
EP (1) EP0732930B1 (no)
JP (2) JPH11501284A (no)
KR (1) KR960706350A (no)
CN (1) CN1140998A (no)
AT (1) ATE302015T1 (no)
AU (1) AU678090B2 (no)
CA (1) CA2177825A1 (no)
DE (1) DE69434459T2 (no)
FI (1) FI962246L (no)
HU (1) HUT76096A (no)
NO (1) NO962187L (no)
NZ (1) NZ277403A (no)
WO (1) WO1995015173A1 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161771C (en) * 1993-04-30 2009-01-13 L. David Tomei Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5620888A (en) * 1994-12-29 1997-04-15 Lxr Biotechnology, Inc. Cell strains for use in identifying potentially therapeutically effective agents
CN1200036A (zh) * 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
CA2266325C (en) 1996-09-24 2012-07-17 Lxr Biotechnology, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070299005A1 (en) 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
IL119535A (en) * 1996-10-31 2001-01-11 Chajuss Daniel Soy molasses and modified soy molasses for topical application
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
EP0973384A4 (en) 1997-02-13 2004-10-13 Sky High Llc ORGAN PRESERVATION SOLUTION
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
CA2301921A1 (en) * 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
EP0911634A1 (en) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmaceutical uses of CDK-2 regulators
AU3191599A (en) * 1998-03-18 1999-10-11 Lxr Biotechnology Inc. Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US5869063A (en) * 1998-06-29 1999-02-09 Protease Sciences, Inc. Dermatological and cosmetic compositions containing marama bean extract
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
CN1176941C (zh) * 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
CN1235875C (zh) 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
WO2001043750A1 (en) * 1999-12-14 2001-06-21 Sky High, Llc Phospholipid compositions as anti-inflammation agents
US20070048726A1 (en) * 2000-01-14 2007-03-01 Biolife Solutions, Inc. Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State
US20060063738A1 (en) * 2000-02-28 2006-03-23 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
US6861077B1 (en) * 2000-03-17 2005-03-01 L'oreal S.A. Use of plant extracts in a cosmetic composition to protect keratinous fibers
CA2458068A1 (en) * 2001-08-20 2003-02-27 Tatton Technologies, Llc. Methods and compositions for treating apoptosis associated disorders
US20030077264A1 (en) * 2001-09-20 2003-04-24 Goodrich Laura L. Antimicrobial blood treatment using allicin and related compounds
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
JP2005537006A (ja) * 2002-08-28 2005-12-08 ダイアックス、コープ 臓器及び組織の保存方法
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
MXPA05002640A (es) * 2002-09-13 2005-07-19 Olin Corp Aleacion a base de cobre que endurece por envejecimiento y proceso.
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
WO2005091823A2 (en) 2004-03-01 2005-10-06 The Regents Of The University Of California The use of lunasin peptide as a transcriptional activator to prevent cancer and related methods for treatment, monitoring and prognosis
US20060035827A1 (en) * 2004-06-24 2006-02-16 Green Gary M Compositions and methods for the treatment or prevention of gallbladder disease
US7691417B2 (en) 2004-09-02 2010-04-06 Clemson University Research Foundation Tumor and mutation suppressing plant extract
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US8187643B2 (en) * 2007-03-28 2012-05-29 Greg Steininger, legal representative Shampoo formulation for treatment of hair loss and method of use
WO2010005560A2 (en) * 2008-07-07 2010-01-14 Woods Hole Oceanographic Institution Methods for obtaining bioactive compounds from phytoplankton
CA2744235A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US9217741B2 (en) * 2009-11-05 2015-12-22 Woods Hole Oceangraphic Institution Bioactive compounds from phytoplankton containing glycosidic residue for apoptosis and cancer treatment
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US12528880B2 (en) 2020-01-13 2026-01-20 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) * 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
EP0200757B1 (en) * 1984-10-19 1992-03-11 Chiron Corporation Promotion of wound healing with human epidermal growth factor prepared from recombinant dna
US4793996A (en) * 1984-11-14 1988-12-27 Ann R. Kennedy Method of making soybean extract inhibitor
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
JPS62155082A (ja) * 1985-12-27 1987-07-10 Karupisu Shokuhin Kogyo Kk ビフイズス菌増殖物質の製造法
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
JPS6351335A (ja) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US4959310A (en) * 1987-09-28 1990-09-25 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to soybean kunitz trypsin inhibitor and immunoassay methods
US5053327A (en) * 1988-09-20 1991-10-01 The United States Of America As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies to bowman-birk inhibitor and immunoassay methods
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2809429B2 (ja) * 1989-05-26 1998-10-08 湧永製薬株式会社 制ガン剤ならびに制ガン剤として有用な新規複素環化合物またはそれらの塩
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
US5376373A (en) * 1990-09-06 1994-12-27 Trustees Of The University Of Pennsylvania Method of inhibiting radiation induced weight and hair loss
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
US5340568A (en) * 1992-07-01 1994-08-23 The Procter & Gamble Company Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles
US5636187A (en) 1992-12-11 1997-06-03 Canon Kabushiki Kaisha Magnetooptical recording apparatus and magnetooptical recording method for canceling leakage magnetic fields associated with a recording medium and devices ancillary to the recording medium
US5277917A (en) * 1993-04-02 1994-01-11 Allelix Biopharmaceuticals Inc. Ovarian cancer ascites factor, in isolated form
CA2161771C (en) * 1993-04-30 2009-01-13 L. David Tomei Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US5330972A (en) * 1993-05-28 1994-07-19 Abbott Laboratories Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
NZ248603A (en) * 1993-05-28 1994-12-22 Abbott Lab Nutritional product for enteral nutritional support of hiv victims comprising proteins and fat
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Also Published As

Publication number Publication date
FI962246A0 (fi) 1996-05-29
FI962246A7 (fi) 1996-07-22
US5624672A (en) 1997-04-29
DE69434459T2 (de) 2006-04-06
US5620885A (en) 1997-04-15
WO1995015173A1 (en) 1995-06-08
AU1261295A (en) 1995-06-19
US6306398B1 (en) 2001-10-23
EP0732930A4 (en) 1997-10-29
EP0732930B1 (en) 2005-08-17
JP2007084573A (ja) 2007-04-05
US5635187A (en) 1997-06-03
HUT76096A (en) 1997-06-30
AU678090B2 (en) 1997-05-15
DE69434459D1 (de) 2005-09-22
US6656729B2 (en) 2003-12-02
FI962246L (fi) 1996-07-22
ATE302015T1 (de) 2005-09-15
CA2177825A1 (en) 1995-06-08
KR960706350A (ko) 1996-12-09
JPH11501284A (ja) 1999-02-02
US5759548A (en) 1998-06-02
US20020110608A1 (en) 2002-08-15
US5635186A (en) 1997-06-03
HU9601449D0 (en) 1996-07-29
NZ277403A (en) 1998-03-25
CN1140998A (zh) 1997-01-22
US5567425A (en) 1996-10-22
NO962187L (no) 1996-07-30
EP0732930A1 (en) 1996-09-25

Similar Documents

Publication Publication Date Title
NO962187D0 (no) Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
NO942170L (no)
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
ES544051A0 (es) Procedimiento para preparar nuevos derivados de benzazocino-na y de benzaconinona
NO944430D0 (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DK0705100T3 (da) Terapeutiske substituerede guanidiner
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
NO995544L (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
DK0625987T3 (da) Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
BR9811099A (pt) Inibidores de urocinase
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK1112067T3 (da) Anvendelse af acetylcholinesteraseinhibitorer til fremstilling af farmaceutiske præparater til behandling af funktionelle og/eller organiske smertesyndromer
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
DK0888323T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
SE9801494D0 (sv) Novel use
ATE213937T1 (de) Spezielle halofantrinhaltige zusammensetzungen
DK0975588T3 (da) Antipicornavirale forbindelser, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse
BG100248A (bg) Инхибитори на скваленсинтетаза
ATE301933T1 (de) Akarizidpulver
NO20044700L (no) Ny assoiasjon av et antitrombotisk middel og aspirin